In this article:

PAVmed (PAVM) Receives a Buy from Maxim Group

In this article:
In this article:

Maxim Group analyst Anthony Vendetti maintained a Buy rating on PAVmed (PAVMResearch Report) yesterday and set a price target of $10.00. The company’s shares closed last Wednesday at $3.89.

According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 12.2% and a 40.8% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Dermata Therapeutics, ReShape Lifesciences, and Milestone Scientific.

Currently, the analyst consensus on PAVmed is a Moderate Buy with an average price target of $10.00.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $9.70 and a one-year low of $1.63. Currently, PAVmed has an average volume of 2.41M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Read More on PAVM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed